---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-22-000005"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-02-03T23:59:59+00:00"
generated_at: "2026-06-27T11:29:12.236210+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFO Elaine Sun steps down; Nicole LaBrosse appointed effective Feb 2, 2022

## Summary
- Elaine Sun left immediately to pursue another opportunity; separation agreement expected.
- Nicole LaBrosse, previously VP Finance and Accounting since 2020, named CFO.
- LaBrosse's initial base salary set at $485,500 with 45% bonus target.
- LaBrosse has 18+ years of public accounting and corporate finance experience, including at PwC.
- CEO Dr. Helen Torley highlighted LaBrosse's internal knowledge and financial skill set.

## SEC filing metadata
- accession: 0001159036-22-000005
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/halo-20220202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-22-000005
- JSON: https://secwatch.observer/filing/0001159036-22-000005.json
- Plain text: https://secwatch.observer/filing/0001159036-22-000005.txt

## Key facts
- Executive change
  Elaine Sun departed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..
  - Action: stepped down
  - Role: Senior Vice President, Chief Financial Officer
  source text: On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm
- Executive change
  Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..
  - Action: appointed
  - Role: Senior Vice President, Chief Financial Officer
  source text: On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.